Srihari S. (Hari) Naidu, MD, FACC, FAHA, FSCAI, Professor of Medicine, New York Medical College, Valhalla, NY, graduated from Brown University in Providence, Rhode Island for both undergraduate and medical school as part of the 8-year program.  Following this, he was a resident at New York Presbyterian Hospital – Cornell Medical Center in Manhattan, and then a cardiology and interventional cardiology fellow at the University of Pennsylvania in Philadelphia, Pennsylvania.  After several years as an attending at New York Presbyterian – Cornell and NYU Winthrop, he moved to Westchester Medical Center and New York Medical College where he runs both the Hypertrophic Cardiomyopathy National Center of Excellence and the Cardiac Catheterization Laboratories.

Dr. Naidu is triple board certified in Internal Medicine, Cardiology and Interventional Cardiology, and has been featured in Westchester Magazine and on the cover of Cardiovascular Business, both of which highlighted his national role in Hypertrophic Cardiomyopathy, the most common cause of sudden cardiac death in athletes and a common cause of heart failure.  Dr. Naidu is a pioneer in the minimally-invasive alternative to open heart surgery known as Alcohol Septal Ablation, and performs the highest volume annually of this procedure in the United States.

Hari currently resides in Manhattan, NY.

Professional Interests:

Dr. Naidu’s areas of professional interest include (1) Hypertrophic Cardiomyopathy and the evaluation and management of sudden cardiac death in the young, (2) treatment of advanced heart failure and Cardiogenic Shock, and (3) minimally-invasive techniques to prevent stroke while avoiding blood thinners, including PFO closure and Left Atrial Appendage Closure.

A specialist in Hypertrophic Cardiomyopathy, patients travel from across the country routinely for his expertise, particularly for the procedure known as Alcohol Septal Ablation.  The HCM Center at Westchester Medical Center is one of the ten busiest in the nation, treating thousands of patients with this disease.  Dr. Naidu edits the only comprehensive textbook, Hypertrophic Cardiomyopathy (Springer, Inc.), now in 2nd Edition, and also runs an annual live proctoring course for others interested in learning the technique and bringing it back to their hospital.

Dr. Naidu is also an expert in Cardiogenic Shock and mechanical support devices to help the failing heart.  In 2019 he chaired the writing group on a new global definition of cardiogenic shock that has become the standard across the world, and he has been instrumental in both developing technologies for Cardiogenic Shock and validating the definition.

Dr. Naidu has over 175 original manuscripts, book chapters and review articles, and lectures widely across the United States, Europe and Asia on his topics of expertise.  A regularly invited speaker at the American Heart Association (AHA) and the American College of Cardiology (ACC), he has chaired several national guidelines and consensus documents on behalf of both organizations.

Dr. Naidu holds several national professional roles including Past Trustee of the Society for Cardiovascular Angiography and Interventions (SCAI), Trustee Emeritus of Brown University, and Past President of the Brown University Medical School Board of Directors.  He is currently President-Elect of the New York Chapter of the ACC where he will represent all cardiologists within State from 2021 to 2024, in Albany, NY and will sit on the Board of Governors of the National ACC in Washington, DC.

Education Profile:

Internal Medicine: New York Presbyterian – Cornell Medical Center, 1997-2000 Cardiology: University of Pennsylvania, 2000-2003 Interventional Cardiology: University of Pennsylvania, 2003-2004 Graduate Degree: M.D. Graduate Degree Institution: Brown University

Other Credentials:

Board Certification: Internal Medicine, 2000; Cardiology 2003; Interventional Cardiology 2004 Licenses:  New York, Michigan, Pennsylvania Current Hospital Affiliation: Attending Cardiologist, Westchester Medical Center; Director, Hypertrophic Cardiomyopathy; Director, Cardiac Catheterization Laboratories